TG Therapeutics (TGTX) Completes Enrollment into Part 1 of Ongoing Phase 2 Study of TG-1101
Tweet Send to a Friend
TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the completion of enrollment into Part 1 of its ongoing Phase 2 study ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
